Login to Your Account



Humira in crosshairs as Amgen gets first phase III biosimilars win

By Marie Powers
Staff Writer

Wednesday, October 8, 2014
Amgen Inc. put the biopharma world on notice by disclosing positive findings from the first phase III study evaluating efficacy and safety of its lead biosimilar candidate.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription